Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EDIT vs BEAM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EDIT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 4–4 Matrix Metrics)

EDIT Overall Winner 6-Pillar Tally: EDIT 5 – 1 BEAM Matrix Metrics: EDIT 4 – 4 BEAM

As of Nov 16, 2026, Editas Medicine, Inc. (EDIT) is the stronger overall head-to-head candidate over Beam Therapeutics Inc. (BEAM) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EDIT carries a Unified Composite Score of 51.6/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin), whereas BEAM carries 45.9/100 (HOLD) at $21.29 (N/M Forward P/E, -267.7% operating margin).

  • Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1); meanwhile BEAM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EDIT vs BEAM
EDIT NASDAQ Head-to-Head Winner
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 35
RSI-14: 35.1 · SMA20: $2.52 · SMA50: $2.61
BEAM NASDAQ
Beam Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$21.29
-6.75% 1D
Market Cap $2.4B
TTM Revenue $147M
Forward P/E N/M
Beta / 30D Vol 2.24β · 86% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 30.0 Fund 52.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 37
RSI-14: 37.3 · SMA20: $25.54 · SMA50: $24.99

6-Pillar Scorecard Institutional Category Breakdown (EDIT 5 – 1 BEAM)

Columns: Metric · EDIT · BEAM
1. Valuation Multiples EDIT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 5.2x 16.8x
2. Growth & Scale BEAM
Revenue Growth (YoY) +37.4% -96.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $50M $147M
Market Cap $336.5M $2.4B
3. Profitability & Quality EDIT
Gross Margin -73.3% N/A
Operating Margin -167.0% -267.7%
Net Profit Margin -144.9% -73.9%
Return on Equity (ROE) -147.4% -11.3%
4. Balance Sheet & Cash Flow EDIT
Cash Generation (TTM) -$110M -$398M
Cash Flow Margin N/A N/A
Net Cash / Leverage $79M Net Cash $31M Net Debt (0.26x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EDIT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 95.8% (38th %ile) 66.0% (42nd %ile)
Put/Call OI Skew 0.29x (Call-Skewed) 0.47x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EDIT (4) vs BEAM (4)
Institutional Metric EDIT BEAM Criterion Row Edge
Market Capitalization
Scale
$336.5M $2.4B Larger Scale BEAM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+37.4% -96.8% Higher Growth EDIT
Operating Margin (TTM)
Profitability
-167.0% -267.7% Higher Margin EDIT
Net Profit Margin
Profitability
-144.9% -73.9% Higher Margin BEAM
Return on Equity (ROE)
Capital Efficiency
-147.4% -11.3% Higher ROE BEAM
52-Week Range Position
Momentum
11% ($2–$4) 6% ($20–$38) Stronger Trend EDIT
Beta / 30D Volatility
Risk Regime
2.32β · 102% Vol 2.24β · 86% Vol Lower Realized Risk BEAM
Unified Institutional Score
Composite Signal
51.6 / 100 (HOLD) 45.9 / 100 (HOLD) Higher Composite EDIT
Trailing 12M Revenue (USD)
Operating Scale
$50M $147M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-73.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.2x EV/Rev N/M PEG · 16.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($79M Net Cash) -$398M ($31M Net Debt (0.26x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BEAM +9.65 pp
EDIT: -18.94% · BEAM: -9.29%
3M Horizon BEAM +13.98 pp
EDIT: -33.85% · BEAM: -19.87%
6M Horizon BEAM +4.11 pp
EDIT: -24.7% · BEAM: -20.59%
1Y Horizon BEAM +23.29 pp
EDIT: -25.0% · BEAM: -1.71%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EDIT Revenue BEAM Revenue EDIT Op. Margin BEAM Op. Margin Margin Leader
FY2018 $30M N/A -356.1% N/A EDIT
FY2019 $20M $0M -686.4% -417522.2% EDIT
FY2020 $90M $0M -148.6% -553166.7% EDIT
FY2021 $30M $50M -756.1% -757.0% EDIT
FY2022 $20M $60M -1146.3% -555.6% BEAM
FY2023 $80M $380M -216.6% -46.7% BEAM
FY2024 $30M $60M -777.2% -654.3% BEAM
FY2025 $40M $140M -394.9% -274.6% BEAM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BEAM BREAKDOWN
103d in phase · OBV DISTRIBUTION
Current IV 66.0%
IV Percentile 42nd %ile
Put/Call OI Skew 0.47x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BEAM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
BEAM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4B market capitalization and -267.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EDIT vs BEAM Key Questions & Quantitative Answers

As of Nov 16, 2026, Editas Medicine, Inc. (EDIT) is the stronger overall head-to-head candidate over Beam Therapeutics Inc. (BEAM) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EDIT carries a Unified Composite Score of 51.6/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin), whereas BEAM carries 45.9/100 (HOLD) at $21.29 (N/M Forward P/E, -267.7% operating margin). Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1); meanwhile BEAM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BEAM leads the Growth & Scale pillar: EDIT posts +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin), compared with BEAM at -96.8% YoY revenue growth and +0.0% YoY earnings growth on $147M TTM revenue (N/A gross margin, -267.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EDIT cumulative revenue shifted +33.3% while BEAM shifted +180.0%. In operating R&D and SG&A reinvestment, EDIT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BEAM.

EDIT screens cheaper on headline valuation multiples. EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin), whereas BEAM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EDIT (-147.4% ROE) versus BEAM (-11.3% ROE) capital efficiency.

In options market volatility and institutional positioning, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk). By comparison, BEAM carries 66.0% implied volatility (42nd %ile, Balanced (25th–60th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.